Research Paper Volume 13, Issue 4 pp 5312—5331

Evaluation of the prognostic values of solute carrier (SLC) family 39 genes for patients with lung adenocarcinoma

GO enriched analysis, GSEA analysis and co-expression analysis of SLC39A7 in lung adenocarcinoma. (A) Heat-map showed the DEGs of SLC39A7. (B) GO enriched analysis (CC) for SLC39A7. (C) GSEA of Wnt/β-catenin signaling pathway. (D) Co-expression of SLC39A7 and RRBP1 by using cBioportal database. (E) RRBP1 expression of mRNA in LUAD tissues and relative normal tissues in Ualcan database. (F) Kaplan-Meier plotter was used to evaluate prognostic value (OS) of RRBP1 in lung adenocarcinoma. A549 cells were transfected with a control siRNA or siRNA-SLC39A7 (G)/ RRBP1 (H). Western blotting was performed to detect the expression of SLC39A7 and RRBP1. (I) Immunohistochemistry assays were performed to detect expression and distribution of SLC39A7 and RRBP1 proteins in lung adenocarcinoma tissues. DEG, differentially expressed genes; GSEA, Gene Set Enrichment Analysis; RRBP1, ribosome binding protein 1; SLC39A, solute carrier family 39.

Figure 6. GO enriched analysis, GSEA analysis and co-expression analysis of SLC39A7 in lung adenocarcinoma. (A) Heat-map showed the DEGs of SLC39A7. (B) GO enriched analysis (CC) for SLC39A7. (C) GSEA of Wnt/β-catenin signaling pathway. (D) Co-expression of SLC39A7 and RRBP1 by using cBioportal database. (E) RRBP1 expression of mRNA in LUAD tissues and relative normal tissues in Ualcan database. (F) Kaplan-Meier plotter was used to evaluate prognostic value (OS) of RRBP1 in lung adenocarcinoma. A549 cells were transfected with a control siRNA or siRNA-SLC39A7 (G)/ RRBP1 (H). Western blotting was performed to detect the expression of SLC39A7 and RRBP1. (I) Immunohistochemistry assays were performed to detect expression and distribution of SLC39A7 and RRBP1 proteins in lung adenocarcinoma tissues. DEG, differentially expressed genes; GSEA, Gene Set Enrichment Analysis; RRBP1, ribosome binding protein 1; SLC39A, solute carrier family 39.